AXN-2510 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new treatment called AXN-2510 for individuals with advanced solid tumors that have recurred or do not respond to standard treatments. The trial aims to determine the side effects, optimal dose, and duration of the drug in the body. Participants will receive the treatment via IV every three weeks and will undergo regular checkups. This trial suits those without other standard treatment options who can provide specific tumor information. Participants should not have active brain metastases or be on immune-suppressing medications. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new drug.
Do I have to stop taking my current medications for the trial?
The trial requires that you stop any prior treatment within 5 half-lives or 4 weeks before starting AXN-2510, whichever is shorter, except for certain hormone therapies for prostate or breast cancer. If you are using immune-suppressive medication, you may need to stop, with some exceptions.
Is there any evidence suggesting that AXN-2510 is likely to be safe for humans?
Earlier studies tested AXN-2510 in people with cancer. These studies showed that the treatment was generally well-tolerated. Some patients experienced side effects, but these were mostly mild or moderate. Importantly, no unexpected safety problems emerged. This early information suggests that AXN-2510 is quite safe for humans, but further research is underway to understand any possible risks. As this trial is in an early stage, it is specifically designed to carefully assess safety and determine the best dose.12345
Why do researchers think this study treatment might be promising?
Unlike the standard cancer treatments, which often involve chemotherapy targeting rapidly dividing cells, AXN-2510 offers a novel approach by specifically targeting unique cancer cell markers. This targeted mechanism of action minimizes damage to healthy cells, potentially reducing side effects. Moreover, AXN-2510 is administered via intravenous infusion every three weeks, which is less frequent than some current therapies, potentially improving patient convenience and adherence. Researchers are excited about AXN-2510 because it represents a promising new direction in personalized cancer treatment, offering hope for more effective and tolerable options.
What evidence suggests that AXN-2510 might be an effective treatment for cancer?
Research has shown that AXN-2510, the investigational treatment tested in this trial, has promising early results for certain types of non-small cell lung cancer (NSCLC). In studies, 80% of patients with squamous NSCLC and 46% with nonsquamous NSCLC experienced partial tumor shrinkage. Among 17 evaluable patients, about one-third showed some reduction in tumor size. These early findings suggest that AXN-2510 may help reduce tumors in some patients with advanced cancer. However, more research is needed to fully understand its effects on different cancer types.12456
Who Is on the Research Team?
Jill I Loftiss, RN
Principal Investigator
Instil Bio
Are You a Good Fit for This Trial?
This trial is for adults with advanced solid tumors who are seeking new treatment options. Participants must be able to attend regular clinic visits and comply with the study procedures.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive AXN-2510 as an intravenous infusion every 3 weeks, with dose escalation based on entry time into the study
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- AXN-2510
Find a Clinic Near You
Who Is Running the Clinical Trial?
Axion Bio, Inc
Lead Sponsor
Instil Bio
Industry Sponsor
Axion Bio
Collaborator